Bishal Gyawali: Are U.S. patients paying twice for cancer drugs?
Bishal Gyawali, Associate Professor at Queen’s University, shared on X:
“Are U.S. patients paying twice for cancer drug like Xtandi- first by supporting its development through taxpayer’s dollars and then by paying the highest price in the world for the same drug?”
Government Funding for the Development of Enzalutamide
Authors: Bishal Gyawali et al.
Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives. Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023